To The Moon

Healthcare stocks performed well during Trump's first term, despite increased uninsured rates and reduced regulation, with insurance companies outperforming biotech and pharma sectors. Reduced federal research funding and high interest rates negatively impacted biotech and pharma, causing underperformance and highlighting potential future risks in these sectors. A favorable business environment under Trump, particularly for M&A, could benefit struggling biotechs, though regulatory and quality control risks remain significant. Diversification is key; consider broad healthcare ETFs like XLV, private insurers via IHF, and equipment makers via XHE to mitigate individual company risks. filo/E+ via Getty Images The major factors influencing the healthcare industry during Trump's first term w

Summary A summary of my holdings and performance through August 2024. I reflect on my investment journey, focusing on transparency, risk management, and personal financial circumstances. Current holdings include a mix of cash, fixed income, real estate, and equity investments, with a focus on healthcare. Lessons learned include the importance of clarity on valuation, avoiding speculative bets, and adjusting for momentum in investment decisions. Cn0ra Introduction I have discussed many investments over the course of four years on the Seeking Alpha platform. Many are based on my own investments using my hard-earned cash. But as I have trained my own research abilities, I have shifted to providing data to my readers that is useful regardless of personal financial circumstances and goals. Part

Summary Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive margins, and focus on next-generation therapies. While Medpace lacks diversification compared to WuXi Biologics, a pair trade strategy can help reduce risk and take advantage of the opportunities in the healthcare market. pengpeng/E+ via Getty Images Introduction Medpace Holdings (NASDAQ:MEDP) is a US-Based clinical research organization, or CRO. With distinct financials and growth orientation that place the firm well above the competition in the non-manufacturing space, it is clear that

Summary Caterpillar Inc. has been successful due to share buybacks, increasing profit margins, and consistent free cash flow generation. Metso Oyj and Epiroc are two smaller peers that have the potential to replicate Caterpillar's success and offer unique growth opportunities. In particular, the mining industry is expected to see lasting demand, providing an opportunity for all three companies to thrive despite broader market risk. Pro-syanov Introduction Caterpillar Inc. (NYSE:CAT) is an industrial conglomerate that leads across construction, mining, and heavy industry. The company has been fairly consistent over the past three decades despite broader industry cyclicality thanks to conservative financial practices. Kinda like that old outd

BalkansCat/iStock Editorial via Getty Images Introduction Getinge AB (OTCPK:GNGBY) is a Swedish Healthcare Medical Tech company focusing on three revenue segments: Acute Care, Life Sciences, and Surgical Workflows. The company is small, valued at a $5 billion USD market cap, but offers a leading position across multiple unique niches within its target markets. This includes multiple #1 market share positions over giant competitors like Medtronic (MDT), GE Healthcare (GEHC), and STERIS (STE). Also, thanks to one recent acquisition, Getinge is now looking to battle the goliaths of Thermo Fish